<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Bu Q</submitter><pubmed_abstract>&lt;b>Purpose:&lt;/b> The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB). &lt;b>Methods:&lt;/b> Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010-2019 were obtained from the Global Burden of Disease Study 2019. The incidence trends of MDR-TB and XDR-TB were evaluated using the estimated annual percentage changes (EAPCs) in ASRs. The relationships among the ASRs of MDR-TB and XDR-TB, the MDR rate, the XDR rate, and socio-demographic index (SDI) were assessed using locally weighted regression and Pearson's correlation coefficient. &lt;b>Results:&lt;/b> The global ASR of MDR-TB on average decreased by 1.36% (EAPC = -1.36, 95% confidence interval [CI] = -2.19 to -0.52) per year whereas that of XDR-TB was stable (EAPC = 0.69, 95% CI = -0.15-1.54) during 2010-2019. The incidence trends of MDR-TB in most regions and countries were decreasing, but those of XDR-TB were increasing. People aged 35-44 and 55-64 years had the highest incidence rates for MDR-TB and XDR-TB. The MDR and XDR rates both peaked in those aged 35-44 years. Areas with higher SDI tended to have lower ASRs of MDR-TB (&lt;i>p&lt;/i> &lt; 0.001, &lt;i>ρ&lt;/i> = -0.43). &lt;b>Conclusion:&lt;/b> The current achievements for the incidence trends of MDR-TB and XDR-TB are insufficient. More strategies and tools need to be developed to further curb MDR-TB and XDR-TB, especially in high-risk areas and age groups, and in low SDI regions.</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1156249</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9998482</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019.</pubmed_title><pmcid>PMC9998482</pmcid><pubmed_authors>Peng X</pubmed_authors><pubmed_authors>Qiang R</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Bu Q</pubmed_authors><pubmed_authors>Fang L</pubmed_authors><pubmed_authors>Cheng H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019.</name><description>&lt;b>Purpose:&lt;/b> The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB). &lt;b>Methods:&lt;/b> Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010-2019 were obtained from the Global Burden of Disease Study 2019. The incidence trends of MDR-TB and XDR-TB were evaluated using the estimated annual percentage changes (EAPCs) in ASRs. The relationships among the ASRs of MDR-TB and XDR-TB, the MDR rate, the XDR rate, and socio-demographic index (SDI) were assessed using locally weighted regression and Pearson's correlation coefficient. &lt;b>Results:&lt;/b> The global ASR of MDR-TB on average decreased by 1.36% (EAPC = -1.36, 95% confidence interval [CI] = -2.19 to -0.52) per year whereas that of XDR-TB was stable (EAPC = 0.69, 95% CI = -0.15-1.54) during 2010-2019. The incidence trends of MDR-TB in most regions and countries were decreasing, but those of XDR-TB were increasing. People aged 35-44 and 55-64 years had the highest incidence rates for MDR-TB and XDR-TB. The MDR and XDR rates both peaked in those aged 35-44 years. Areas with higher SDI tended to have lower ASRs of MDR-TB (&lt;i>p&lt;/i> &lt; 0.001, &lt;i>ρ&lt;/i> = -0.43). &lt;b>Conclusion:&lt;/b> The current achievements for the incidence trends of MDR-TB and XDR-TB are insufficient. More strategies and tools need to be developed to further curb MDR-TB and XDR-TB, especially in high-risk areas and age groups, and in low SDI regions.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-04T18:49:04.989Z</modification><creation>2025-04-04T18:49:04.989Z</creation></dates><accession>S-EPMC9998482</accession><cross_references><pubmed>36909179</pubmed><doi>10.3389/fphar.2023.1156249</doi></cross_references></HashMap>